Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Radiotherapy + Anti-PD-1 Neoadjuvant for Locally Advanced HNSCC
NCT07371234Phase 2Recruiting
- Sponsor
- Rui Therapeutics
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Rui Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07371234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371234.